DUBLIN, May 29, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Hemophilia Therapeutics Market By Drug, By Type of Hemophilia, By Treatment, By Therapy Outlook 2022" report to their offering.
The global hemophilia therapeutics market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global hemophilia therapeutics market. The report provides insight about the major drivers, such as increasing awareness about hemophilia and its treatment options, grants and tax credits, for the global hemophilia therapeutics market.
Furthermore, few challenges, such as manufacturing difficulties and low switching rate between hemophilia medicines, which are hindering the growth of the global hemophilia therapeutics market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global hemophilia therapeutics market.
The global hemophilia therapeutics market has been segmented on the basis of type of hemophilia, i.e. Hemophilia A, Hemophilia B, and Others. Hemophilia A occupies the largest share in the global hemophilia therapeutics market, owing to the highest prevalence of this type of hemophilia. Moreover, strong pipeline of drugs for Hemophilia A is also helping its market to grow all across the globe.
- Alnylam Pharmaceuticals, Inc.
- Bayer AG
- CSL Limited
- F. Hoffmann-La Roche Ltd.
- Grifols International SA
- Novo Nordisk A/S
- Octapharma AG
- Pfizer Inc.
- Shire plc
- Swedish Orphan Biovitrum AB
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Hemophilia: An Overview
4. Market Dynamics
5. Global Hemophilia Therapeutics Market Outlook 2022
6. Major Products in Hemophilia Therapeutics Market
7. Market Segmentation by Type of Hemophilia
8. Market Segmentation by Type of Treatment
10. Market Segmentation by Geography
11. Gene Therapy - Future of Hemophilia Treatment
12. Trends & Developments
13. Mergers & Acquisitions
14. Pipeline Analysis
15. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/s9x8n9/global_hemophilia
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716